Novel Full Spectrum Anti-Dengue Antibody
Exclusively Licensed
Invention type: Technology
/
Case number: #16643
The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
Researchers
Ram Sasisekharan
/
Kannan Tharakaraman
Departments: School of Engineering
Technology Areas: Drug Discovery and Research Tools: Antibodies / Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living
-
novel full spectrum anti-dengue antibody
Sri Lanka | Granted | 18,921 -
novel full spectrum anti-dengue antibody
China | Granted | 0 -
novel full spectrum anti-dengue antibody
Singapore | Granted | 11,201,606,163 -
novel full spectrum anti-dengue antibody
Mexico | Granted | 375,402 -
novel full spectrum anti-dengue antibody
United States of America | Granted | 9,902,764 -
novel full spectrum anti-dengue antibody
Hong Kong | Published application -
novel full spectrum anti-dengue antibody
Hong Kong | Granted | 1,233,537 -
full spectrum anti-dengue antibody
United States of America | Granted | 10,519,220 -
novel full spectrum anti-dengue antibody
Australia | Granted | 2,015,217,149 -
novel full spectrum anti-dengue antibody
United States of America | Granted | 11,421,018 -
novel full spectrum anti-dengue antibody
Japan | Granted | 6,707,455
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.